Afya (AFYA) Q1 2025: 24% EBITDA Growth Signals Operating Leverage, Margin Discipline
Afya’s Q1 2025 results highlighted a step-change in operating leverage, with EBITDA margins expanding sharply on disciplined cost management and segment mix improvement. The company’s core undergraduate medical education business remains the main engine, but continuing education and medical practice solutions are showing improved resilience and incremental margin contribution. With a robust cash position and conservative leverage, Afya is positioned to navigate regulatory and competitive headwinds while maintaining its leadership in Brazil’s medical education market.
Summary
- Margin Expansion Outpaces Revenue Growth: Cost discipline and undergrad segment mix drove significant EBITDA margin gains.
- Medical Seat Growth and Brand Strength: Strong intake and renewals reinforce Afya’s moat in medical education.
- Strategic Capital Flexibility: Robust cash generation and low leverage underpin resilience despite new tax and debt provisions.
Performance Analysis
Afya delivered a strong financial quarter with net revenue up 16% year-over-year, led by the undergrad segment, which contributed 86% of segment revenue and saw over 17% growth. The company’s adjusted EBITDA rose 24%, outpacing revenue growth and expanding margins by 300 basis points to a record 52.5%. This margin improvement was driven by a combination of higher average ticket prices in medical courses, the ongoing ramp-up of recently launched campuses, and operational restructuring across continuing education and medical practice solutions.
Operating cash flow was robust, increasing nearly 10% to R$470 million, with a high cash conversion rate of 96.8%. Net income rose 23% despite a R$23 million tax provision related to Brazil’s implementation of OECD Pillar 2 global minimum tax rules. The company’s net debt was reduced by R$291 million quarter-over-quarter, reflecting strong cash generation and prudent capital allocation. The continuing education segment showed signs of acceleration, with net revenue up nearly 9% year-over-year, while medical practice solutions grew 14%, supported by B2B contract ramp-up.
- Undergrad Segment Drives Profitability: 94% of undergrad revenue is health-related, with medical school seats up 12% and student count up 15% year-over-year.
- Continued Education and Medical Practice Solutions Gain Traction: Both segments posted margin expansion and improved cost efficiency, aided by restructuring and B2B growth.
- Cash and Leverage Strengthen: Net debt/EBITDA at 0.9x and R$1.2 billion in cash provide flexibility for regulatory or market shocks.
Afya’s ability to simultaneously grow top line, expand margins, and improve cash flow conversion underscores the resilience and scalability of its business model.
Executive Commentary
"These quarterly results show the high predictability of our business and successful execution of our strategy that once again combines strong growth with higher profitability and cash generation, AFYA's three pillars business model."
Virgílio Gibon, CEO
"The expansion in adjusted EBITDA margin is largely attributed to a strong performance of the undergrad segment, the gross margin expansions in the undergrad and continuing educational segments, the ramp-up of the four Miles Medical campuses that started operations in the third quarter of 2022, the operational restructuring efforts in continual educational and medical practice solutions segments."
Luis André Blanco, CFO
Strategic Positioning
1. Undergrad Segment as Core Growth Engine
Afya’s undergraduate medical education business remains the company’s anchor, accounting for the majority of revenue and margin. The segment benefits from ongoing seat expansion, high occupancy, and pricing power, with nearly 50% growth in student count year-over-year. The recent Funic acquisition and the integration of UNIDON further consolidate Afya’s leadership, while the successful intake process—seven to eight candidates per seat—demonstrates brand strength and sustained demand.
2. Margin Expansion Through Operational Restructuring
Margin gains are being driven by a combination of segment mix, cost control, and restructuring initiatives. The “zero budget project,” launched in 2023, continues to yield SG&A efficiency. Centralization of academic processes and the expansion of the shared service center have improved scalability, while the ramp-up of new campuses delivers operating leverage. Gross margin expansion in both undergrad and continuing education segments has been a key lever.
3. Ecosystem and Data Strategy Reinforce Moat
Afya’s ecosystem now reaches 317,000 active users, including physicians and medical students, providing a platform for cross-selling and data-driven B2B partnerships. The strategic shift to a more restrictive portal aims to deepen user data capture, supporting future monetization and strengthening B2B relationships with pharmaceutical partners. The company’s ESG and credit upgrades (MSCI BBB, Moody’s AAA.br) also enhance its institutional credibility.
4. Regulatory and Tax Resilience
Management is proactively addressing regulatory headwinds, including the OECD Pillar 2 minimum tax, by provisioning and challenging elements in court. The company’s strong cash flow and low leverage provide a cushion against potential cash outflows or debt redemption pressures, such as the upcoming SoftBank convertible debt maturity.
Key Considerations
Afya’s Q1 2025 results reveal a business model that is both scalable and resilient, with multiple levers for growth and profitability. The quarter also surfaces several important considerations for investors as Afya navigates a complex regulatory and competitive landscape.
Key Considerations:
- Operating Leverage in Core Segment: Undergrad medical education continues to deliver margin and cash flow, with new seat additions and high intake ratios sustaining growth.
- Restructuring Benefits Flowing Through: Cost efficiency from centralized processes and the zero budget initiative are now fully embedded, supporting margin expansion.
- Data Monetization and B2B Ramp: The ecosystem model and portal changes are designed to strengthen B2B revenue, particularly from pharmaceutical contracts, despite some near-term user friction.
- Tax and Debt Provisions Managed Conservatively: Proactive provisioning for OECD Pillar 2 tax and SoftBank debt premium reflects prudent risk management, preserving capital flexibility.
Risks
Afya faces several risks, including regulatory uncertainty around OECD Pillar 2 tax implementation, competitive pressure in residency and prep programs, and potential intake headwinds if seat supply outpaces demand. The medical practice solutions segment’s user base remains in transition after the portal migration, with some risk of further engagement erosion if the new data capture model is not well received. Upcoming SoftBank debt redemption in 2026 could also test liquidity if not converted to equity.
Forward Outlook
For Q2 2025, Afya guided to:
- Maintain revenue and EBITDA guidance set in March, with upside possible after second semester intake.
- Continue operational focus on margin expansion and efficiency, with no change to full-year targets at this stage.
For full-year 2025, management maintained guidance:
- Revenue and adjusted EBITDA in line with prior outlook, pending intake and renewal trends in the second semester.
Management highlighted several factors that will shape the year:
- Strong intake and renewal rates support confidence in student base growth.
- Monitoring competitive dynamics and regulatory developments, particularly around tax and debt obligations.
Takeaways
Afya’s Q1 results demonstrated the scalability and predictability of its medical education platform, with margin expansion driven by cost discipline and segment mix.
- Margin Expansion Anchored by Core Segment: Undergrad medical education remains the key profit driver, with operational leverage from new seat additions and high occupancy.
- Strategic Restructuring Delivers Results: Efficiency initiatives and centralization efforts are now translating into sustainable margin gains and improved cash flow.
- Future Watchpoints: Monitor regulatory and tax outcomes, intake dynamics as seat supply grows, and the ramp-up of B2B and ecosystem monetization for incremental upside.
Conclusion
Afya’s Q1 2025 performance underscores the strength of its business model, with disciplined execution driving both growth and profitability. While regulatory and competitive headwinds persist, the company’s operational and financial flexibility position it well to sustain leadership in Brazil’s medical education market.
Industry Read-Through
Afya’s results highlight the defensive and scalable nature of medical education in emerging markets, where demand for quality seats continues to outpace supply despite regulatory and competitive pressures. Margin expansion through operational restructuring offers a blueprint for other education providers facing similar inflation and compliance headwinds. The company’s data-driven ecosystem and B2B monetization strategy also signal a broader trend toward digital integration and ancillary revenue streams in education and healthcare services. The evolving regulatory landscape, particularly around global minimum tax adoption, will remain a watchpoint for all multinational education and healthcare operators in Brazil and beyond.